Most imaging agents can be seen as frameworks that support and carry imaging elements. The imaging element provides radiopacity or radioactivity, or induces changes in echogenicity or magnetic relaxation times in the tissues.
In medicine liposomes are known as potential carriers for therapeutic agents. The utilization of liposomes as vehicles for contrast agents has been proposed and studied by many (McDougall et al., 1975; Caride et al., 1976; Richardson et al., 1978; , and is the subject of the present paper. There are important differences between therapeutic and diagnostic uses of liposomes. For example, the targeting in imaging is not mandatory. Although absolute targeting, i.e. delivery of the cargo, only to the target site, is very important for therapy, partial targeting is an acceptable compromise for imaging. In many occasions the delivery of the imaging agent to areas adjacent to the 'target area' will be as effective as the delivery of the agent exclusively to the target (Caride & Sostman, 1983) .
The images are generated by acquiring information from a given area of the body; therefore the requirements for targeting are less demanding, since contrast enhancement results from the relative regional distribution of the tracer between the target and the non-target tissues. When this ratio is high the target can be made visible, even if only a small fraction of the administered dose is present in the area under scrutiny.
In short, liposomes can provide an additional protective structure for the imaging agent, alter its pharmacokinetics with potential selective organ or lesion enhancement, amplify the contrast-enhancement effect, transport multiple imaging agents at once and decrease toxicity.
There are two basic approaches: to use liposomes as vehicles for conventional imaging agents or to transform liposomes into the framework that carries the imaging element. In the last instance radioactive, radiopaque, sonoreflective or paramagnetic elements form part of the lipid vesicles. In this paper we refer to radiolabelled and radiopaque liposomes.
Radiolabelled liposomes
A central consideration is the incorporation of the imaging element in the lipid vesicle. Radiotracers can be entrapped in the aqueous phase or attached to a lipidsoluble molecule that is inserted in the lipid bilayer. Both techniques have advantages and disadvantages. Furthermore, consideration should be given to the properties of the radiotracer in vivo.
One strategy is to label the lipid vesicles with a tracer that is retained at the site of release. If liposomes are to be used as biological probes, their composition should contemplate the possibility of destabilization when certain environmental conditions are present : variations in pH, temperature, presence of phospholipases or other products of necrosis. In these cases the radiotracer should dissociate from the lipid vesicle as a consequence of the noxious stimuli and accumulate locally. We evaluated in normal mice the use of an aqueous tracer, 99mTc-DTPA*, and of a lipid labe1,l' I In-oxine, in multilamellar lipid vesicles and showed that, whereas the aqueous label after being released from the liposome is eliminated in the urine, the "'Inoxine label remains at the site of liposome-tracer dissociation (Espinola et al., 1979) ( Table 1 ). In effect, the lllln has higher affinity for intracellular ferroproteins than for the oxine molecule. The use of these or similar labels is useful to study the rate of lipsome destruction and to provide a permanent marker for the site of liposome disassembly. Recent papers ( The use of aqueous tracers that may leak out of liposomes has its own merits. We have identified conditions that affect the integrity of liposomes, inducing the release of the contents. In myocardial ischaemia we have shown that in areas of severely decreased blood flow the aqueous tracer 99mTc-DTPA dissociates from liposomes (Caride & Zaret, 1977) . 99mTc-DTPA, as well as other chelates, accumulates in areas of ischaemia; therefore after the local release from liposomes the radiotracer remains associated with the lesion. A similar finding has been reported in ischaemic intestine (Palmer et al., 1981) .
Another application of liposomes is in association with anti-tumour antibodies. In this case liposomes may facilitate the administration of the antibody and carry the radiotracers in its lipid or aqueous compartement, allowing the use of unlabelled antibodies. If this can be accomplished, the use of antibodies for imaging can be greatly simplified.
Antibodies can be attached to lipsomes carrying one or several imaging agents. Alternatively the liposome may carry several antibodies. The liposomes may carry a second antibody directed against a primary anti-tumour antibody, while the imaging element may be attached to the first antibody or to the liposome-antibody complex. The sequence can be reversed, i.e. the liposome carries the first antibody. In any case the unique contribution that a liposome can make is to combine the ability to select any type of imaging element (radioactive, radiopaque, sonoreflective, paramagnetic) to the target specificity that antibodies can provide.
Radio-opaque liposomes
Contrast enhancement in radiology is based on the administration of an agent that contains radiopaque elements to increase the attenuation of the X-rays by the Abbreviation: 99mTc-DTPA, 99mTc-diethylenetriamine penta-acetic acid. tissues. Computer-assisted tomography allows better observation of different tissues on the basis of their relative natural radiodensities. The procedure is far more sensitive than conventional radiography. In spite of its sensitivity there is still a need for contrast enhancement in computerassisted-tomography imaging. Most contrast agents provide good enhancement of organs that are the route of excretion. Contrast enhancement of other organs is short in duration, requiring the acquisition of rapid sequential images to capture the transient density change. It will be practical to have a contrast agent that localizes in selected organs and provides long-lasting density changes. One solution is to infuse the agent while the study is being conducted. This implies the administration of large volumes of the contrast agent, with the predictable inconvenience associated with it.
The use of particulate contrast agents for observation of liver and spleen has been proposed (Fisher, 1977) . Colloidal metal suspensions, although providing permanent enhancement in liver and spleen, are highly toxic and cannot be used (Havron et al., 1980) . Lipid emulsions have been successfully used in animals as well as in humans (Alfidi & LavalJeantet, 1976; Vermess et al., 1977; Lamarque et al., 1979; Vermess et al., 1980) . Large volumes are injected, and in some cases unpleasant side effects have been reported.
We proposed to use liposomes to carry contrast agents (Caride, 198 l) , and evaluated liposomes prepared with iodinated phospholipids and with brominated phospholipids (Caride et al., 1982) . Another approach is the use of liposomes loaded with diatrizoate, a conventional contrast agent, to achieve contrast enhancement of the spleen and liver (Havron et al., 1981) .
Multilamellar liposomes were prepared with brominated or iodinated egg-yolk phosphatidylcholine (Sigma). The chloroform solution of the lipids was evaporated in a roundbottom flask to dryness under a stream of N,. The lipids were resuspended in 0.9% NaCl with the aid of a vortex mixer and bath sonication. Since the preparation of large volumes of liposomes required for certain studies is cumbersome and time consuming, we developed a method for the preparation of liposomes that is simple and brief (V. J. Caride & H. Zacharis, unpublished work). The method allows the use of any lipid mixture and can be automated for industrial preparation. Briefly, fibre glass-wool is embedded in the solution of lipids. The excess is drained and the organic solvent is evaporated under a stream of N2 under vacuum. When the glass-wool/dry-lipid matrix is free of solvent, the aqueous buffer solution is added to the flask and subjected to shaking and/or sonication for a few minutes. Immediately after the addition of the buffer it is possible to observe the lactescent solution of liposomes in the flask. The liposomes are removed and subjected to further processing as desired.
The linear attenuation coefficient of radio-opaque liposomes normalized with respect to water was determined in a fourth-generation Pfizer PZ 600 CT scanner and expressed in Hounsfield units (HU). Table 2 shows the results.
Radio-opaque liposomes prepared with brominated phosphatidylcholine alone or in an 8 : l molar ratio to cholesterol was evaluated in mongrel dogs. The total dose contained approx. log of lipids and 2.7g of bromine in IOOml and was given by slow intravenous injection. The dogs were scanned before and 1, 2 and 3h after injection. The results showed an increase in the linear attenuation coefficient of the liver of 20HU at 2 and 3h. Splenic attenuation changed by 3040HU in two dogs at 3h. However, in one dog there was no discernible change in splenic attenuation. Occasional studies performed 24h after administration of radiopaque liposomes demonstrated persistent splenic opacification. The administration of free NaBr induced transient changes in radiodensity never comparable with that achieved with the radiopaque liposomes. Changes in gall-bladder opacification observed in two animals may be indicative of hepatocytic uptake of liposomes or of transference of the brominated phosphatidylcholine from the original site of uptake to hepatocytes and then bile. Future research should be directed towards a better understanding of the biodistribution and pharmacokinetics of liposomes in normal and abnormal tissues. In the field of imaging, liposome formulations should be tailored to fit the requirements of new technologies. As yet there are few diagnostic applications that may be ready for clinical evaluation; however, in-depth toxicity studies are still lacking. Scale-up procedures for preparation of bulk quantities of liposomes are needed for investigational and industrial purposes.
